In a report released yesterday, Gregory Lewis from BTIG maintained a Hold rating on Genco Shipping (GNK – Research Report). The company’s ...

BTIG analyst Ryan Zimmerman upgraded Treace Medical (TMCI) to Buy from Neutral with a $16 price target The company has pivoted away from ...

BTIG analyst David Larsen adjusted the firm's stance on IQVIA Holdings (NYSE:IQV), moving from a Buy rating to Neutral. The $36.5 billion market cap company, currently trading near its 52-week low at ...

BTIG analyst Mark Massaro announced an increased price target for IDEXX Laboratories (NASDAQ:IDXX), raising it from $500 to $530, while maintaining a Buy rating on the stock. The revision follows ...

Research analysts at BTIG Research reduced their Q4 2025 earnings estimates for shares of D.R. Horton in a research note ...

HOPE Therapeutics™, Inc. ("HOPE"), a medical and technology driven company, and a wholly-owned subsidiary of NRx ...

InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that Yair Malca, Chief Financial Officer will host investor meetings at the BTIG MedTech, ...

Physicians also expect greater use of Johnson & Johnson’s Varipulse system over the next two years despite the company’s ...

What damage might Monday's ongoing selloff do to the technical set-up for stocks? Well, in a note published on Sunday, BTIG chartist guru Jonathan Krinsky observed that Friday's action had already sug ...

Analysts at BTIG moved to the sidelines on online dating apps company Match Group (NASDAQ:MTCH) and lowered its investment rating to "Neutral" from "Buy" on Tuesday. The research firm said its ...

In light of these considerations, Zelin updated BTIG's model to reflect a more moderate differentiation of briquilimab versus barzolvolimab and the decreased likelihood of a Q12W regimen. Despite the ...